CO2019004469A2 - Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) activables y sus usos - Google Patents
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) activables y sus usosInfo
- Publication number
- CO2019004469A2 CO2019004469A2 CONC2019/0004469A CO2019004469A CO2019004469A2 CO 2019004469 A2 CO2019004469 A2 CO 2019004469A2 CO 2019004469 A CO2019004469 A CO 2019004469A CO 2019004469 A2 CO2019004469 A2 CO 2019004469A2
- Authority
- CO
- Colombia
- Prior art keywords
- ctla
- antibodies
- antigen
- tumor
- moiety
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417212P | 2016-11-03 | 2016-11-03 | |
| PCT/US2017/059740 WO2018085555A1 (en) | 2016-11-03 | 2017-11-02 | Activatable anti-ctla-4 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019004469A2 true CO2019004469A2 (es) | 2019-05-10 |
Family
ID=61132883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0004469A CO2019004469A2 (es) | 2016-11-03 | 2019-04-30 | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) activables y sus usos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11117968B2 (enExample) |
| EP (1) | EP3535300B1 (enExample) |
| JP (2) | JP7039582B2 (enExample) |
| KR (2) | KR102584340B1 (enExample) |
| CN (1) | CN110072890B (enExample) |
| AR (1) | AR110678A1 (enExample) |
| AU (1) | AU2017355446A1 (enExample) |
| BR (1) | BR112019008223A2 (enExample) |
| CA (1) | CA3042679A1 (enExample) |
| CL (1) | CL2019001226A1 (enExample) |
| CO (1) | CO2019004469A2 (enExample) |
| EA (1) | EA201990875A1 (enExample) |
| ES (1) | ES3053667T3 (enExample) |
| IL (1) | IL265625A (enExample) |
| MX (1) | MX2019004775A (enExample) |
| MY (1) | MY200695A (enExample) |
| PE (1) | PE20191131A1 (enExample) |
| SG (1) | SG11201902857SA (enExample) |
| TW (2) | TW202334213A (enExample) |
| WO (1) | WO2018085555A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102488220B1 (ko) | 2013-09-25 | 2023-01-12 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| KR102466591B1 (ko) | 2014-01-31 | 2022-11-14 | 싸이톰스 테라퓨틱스, 인크. | 마트립타제 및 ｕ-플라스미노겐 활성화인자 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| BR112019008223A2 (pt) | 2016-11-03 | 2019-07-16 | Bristol-Myers Squibb Company | anticorpos anti-ctla-4 ativáveis e usos dos mesmos |
| MX2019005756A (es) | 2016-11-28 | 2019-08-14 | Chugai Pharmaceutical Co Ltd | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
| TW202235438A (zh) | 2016-11-28 | 2022-09-16 | 日商中外製藥股份有限公司 | 能夠調節配體結合活性的配體結合分子 |
| AU2017414149B2 (en) | 2017-05-19 | 2025-05-15 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| WO2019091384A1 (en) | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| EP3719035A4 (en) * | 2017-11-28 | 2021-09-01 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2019222294A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| JP7414736B2 (ja) | 2018-05-30 | 2024-01-16 | 中外製薬株式会社 | アグリカン結合ドメインおよび運搬部分を含むポリペプチド |
| EP3902833A2 (en) | 2018-12-26 | 2021-11-03 | City of Hope | Activatable masked anti-ctla4 binding proteins |
| MX2021010997A (es) | 2019-03-13 | 2021-10-01 | Merck Sharp & Dohme Llc | Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1. |
| WO2020214748A1 (en) | 2019-04-18 | 2020-10-22 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low ph |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| CN110498856B (zh) * | 2019-09-17 | 2020-08-11 | 浙江玉安康瑞生物科技有限公司 | 一种ctla-4单克隆抗体5h7及其用于抗肿瘤的用途 |
| EP4054723A1 (en) | 2019-11-08 | 2022-09-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| IL294085A (en) | 2019-12-19 | 2022-08-01 | Bristol Myers Squibb Co | Combinations of dgk inhibitors and checkpoint antagonists |
| JP7483896B2 (ja) * | 2020-01-17 | 2024-05-15 | エショー バイオセラピー， インク． | オフターゲット毒性を低下させるプロ抗体 |
| JP2023518835A (ja) * | 2020-03-26 | 2023-05-08 | エショー バイオセラピー， インク． | 制御性ｔ細胞の除去用の二重特異性融合タンパク質 |
| CN115734806A (zh) * | 2020-04-01 | 2023-03-03 | 西里欧发展公司 | 掩蔽的il-12细胞因子和其切割产物 |
| CA3174665A1 (en) * | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| WO2021238932A1 (zh) * | 2020-05-26 | 2021-12-02 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| KR20260042619A (ko) | 2020-08-11 | 2026-03-31 | 재눅스 테라퓨틱스 인크. | 절단 가능한 링커 조성물 및 방법 |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| EP4301781A1 (en) * | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
| CN117500834A (zh) | 2021-06-21 | 2024-02-02 | 百时美施贵宝公司 | 使用蔗糖、甘露糖醇和甘氨酸来减少高浓度冻干生物制剂药物产品的重构时间 |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| US20250333539A1 (en) | 2022-03-23 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| US20260042840A1 (en) | 2022-04-07 | 2026-02-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| US20260049148A1 (en) | 2022-08-01 | 2026-02-19 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| EP4565260A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| AR130080A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024031032A1 (en) | 2022-08-05 | 2024-02-08 | Bristol-Myers Squibb Company | Anti-ctla-4 antibodies for treatment of kras mutant cancers |
| JP2025529279A (ja) * | 2022-09-02 | 2025-09-04 | シクリッド インコーポレイテッド | 抗ｃｔｌａ－４モノクローナル抗体及びその使用 |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| JP2026513839A (ja) | 2023-04-12 | 2026-05-01 | サイトムエックス セラピューティクス，インク． | マスキングポリペプチド、活性化可能サイトカイン構成体、ならびに関連する組成物及び方法 |
| AR134512A1 (es) | 2023-12-01 | 2026-01-21 | Ablynx Nv | Polipéptidos activados con precisión |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| WO2025184211A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
| US20260115307A1 (en) | 2024-10-31 | 2026-04-30 | Bristol-Myers Squibb Company | Anti-fucosyl-gm1 antibody drug conjugates |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| CN102766210B (zh) * | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| JP4334866B2 (ja) | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| CN101160324B (zh) | 2005-02-18 | 2013-04-24 | 米德列斯公司 | 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| EP1976883B1 (en) | 2006-01-17 | 2012-10-03 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
| CA2645347A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| CA2663536A1 (en) | 2006-10-24 | 2008-05-02 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| US8263073B2 (en) | 2008-02-04 | 2012-09-11 | Medarex, Inc. | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| CN102076865B (zh) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| KR20140010076A (ko) * | 2011-02-15 | 2014-01-23 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체 |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| CN110078827A (zh) | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| SG11201408554QA (en) | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| EP2925350B1 (en) * | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| MX2015016329A (es) | 2013-05-28 | 2016-07-20 | Dcb Usa Llc | Bloqueador de anticuerpo para la inactivacion de farmaco de proteina. |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| WO2015053523A1 (ko) * | 2013-10-07 | 2015-04-16 | 한화케미칼 주식회사 | 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법 |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| US10414814B2 (en) | 2014-07-03 | 2019-09-17 | City Of Hope | Tumor-selective CTLA-4 antagonists |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| EP3733696A1 (en) * | 2015-01-13 | 2020-11-04 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| EP3307777A4 (en) | 2015-06-11 | 2019-02-13 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL ANTI-PD-L1 ANTIBODIES |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| MX2018007295A (es) | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| BR112019008223A2 (pt) | 2016-11-03 | 2019-07-16 | Bristol-Myers Squibb Company | anticorpos anti-ctla-4 ativáveis e usos dos mesmos |
| US11939385B2 (en) | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
| CN111278461A (zh) | 2017-08-16 | 2020-06-12 | 百时美施贵宝公司 | 可前药化抗体、其前药以及使用和制备方法 |
-
2017
- 2017-11-02 BR BR112019008223-9A patent/BR112019008223A2/pt not_active IP Right Cessation
- 2017-11-02 WO PCT/US2017/059740 patent/WO2018085555A1/en not_active Ceased
- 2017-11-02 KR KR1020197015448A patent/KR102584340B1/ko active Active
- 2017-11-02 MY MYPI2019002439A patent/MY200695A/en unknown
- 2017-11-02 US US16/347,522 patent/US11117968B2/en active Active
- 2017-11-02 EP EP17837917.8A patent/EP3535300B1/en active Active
- 2017-11-02 PE PE2019000902A patent/PE20191131A1/es unknown
- 2017-11-02 JP JP2019523779A patent/JP7039582B2/ja active Active
- 2017-11-02 MX MX2019004775A patent/MX2019004775A/es unknown
- 2017-11-02 ES ES17837917T patent/ES3053667T3/es active Active
- 2017-11-02 SG SG11201902857SA patent/SG11201902857SA/en unknown
- 2017-11-02 EA EA201990875A patent/EA201990875A1/ru unknown
- 2017-11-02 CA CA3042679A patent/CA3042679A1/en active Pending
- 2017-11-02 CN CN201780066620.7A patent/CN110072890B/zh active Active
- 2017-11-02 AU AU2017355446A patent/AU2017355446A1/en not_active Abandoned
- 2017-11-02 KR KR1020237032965A patent/KR102814027B1/ko active Active
- 2017-11-03 AR ARP170103060A patent/AR110678A1/es unknown
- 2017-11-03 TW TW111141621A patent/TW202334213A/zh unknown
- 2017-11-03 TW TW106138139A patent/TWI784983B/zh not_active IP Right Cessation
-
2019
- 2019-03-26 IL IL265625A patent/IL265625A/en unknown
- 2019-04-30 CO CONC2019/0004469A patent/CO2019004469A2/es unknown
- 2019-05-03 CL CL2019001226A patent/CL2019001226A1/es unknown
-
2021
- 2021-08-11 US US17/399,729 patent/US12441799B2/en active Active
-
2022
- 2022-03-09 JP JP2022036450A patent/JP7472183B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001226A1 (es) | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) activables y sus usos. | |
| MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
| ECSP24031979A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CY1123290T1 (el) | Ενωσεις και μεθοδοι χρησης | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| PE20210633A1 (es) | CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESION DE PNPLA3 Y METODOS DE USO DE LOS MISMOS | |
| CL2019000508A1 (es) | Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados. | |
| CL2020000216A1 (es) | Anticuerpos anti-ctla-4 y sus usos. | |
| ECSP17083788A (es) | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38 | |
| MX2021007468A (es) | Compuestos que participan en la union cooperativa y usos de los mismos. | |
| MX2021003939A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
| PY1947754A (es) | Piridinil y pirazinil-(aza)indolsulfonamidas | |
| PE20201419A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
| CL2021000061A1 (es) | Compuestos inmunomoduladores diméricos contra mecanismos basados en cereblon | |
| BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
| GT201300167A (es) | Mutantes fc de anticuerpos resistentes a proteasas activas | |
| MX2013011261A (es) | Materiales activos para los dispositivos electroopticos y los dispositivos electroopticos. | |
| AR092745A1 (es) | Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer | |
| TWD189366S (zh) | 車尾燈(二) | |
| PE20142046A1 (es) | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma | |
| MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
| MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
| MX2021002301A (es) | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. | |
| CL2021001593A1 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
| MX2017012102A (es) | Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti. |